Reply: Lorazepam-Induced Prolongation of the QT Interval in a Patient With Schizoaffective Disorder and Complete AV Block
Dear Editor: Thank you for the opportunity to respond to Dr Crockford's letter. As active members of a drug safety program in psychiatry in Europe (Arzneimittelsicherheit in der Psychiatrie [AMSP]), we are always interested in discussing complex cases of pharmacotherapy. The AMSP is a drug safety program that ensures the continual assessment of severe adverse drug reactions in psychiatric inpatients under the naturalistic conditions of routine clinical treatment (1) . The AMSP aims to collect information on the type and frequency of severe adverse drug reactions, to identify specific risk factors with regard to patient characteristics and such treatmentrelated factors as interactions caused by drug combinations or drug dosage, and to provide more information on how to adequately handle adverse drug reactions. Currently, 45 hospitals participate in the program.
Recent studies show that a high number of patients with severe cardiac drug reactions have frequent cardiac comorbidity (2) . In addition, most receive drug combinations wherein drugs with similar adverse reaction profiles are often coprescribed. We agree with Dr Crockford that the case we presented and discussed is definitely complex with preexisting cardiovascular risks. However, we do not agree that lorazepam is not possibly associated with QT prolongation in that particular case, and we would like to comment on a few of Dr Crockford's points. First, the electrolyte status revealed no abnormal findings, and the liver enzymes were moderately elevated. Second, the relevance of the half-life of lorazepam in relation to the duration of the QT prolongation is uncertain. Various undesired adverse drug reactions, for example skin reactions and blood dyscrasia, appear after single drug doses. Third, while we agree that a unique mechanism of action for lorazepam, distinct from the other benzodiazepines, seems to be unlikely, daily clinical work shows that substances with almost an identical chemical structure cause different side effects. Fourth, as Dr Crockford points out, there are multiple confounding factors; however, this does not preclude the possibility that lorazepam set off the mechanisms of the persisting QT prolongation.
Inspired by our work in the AMSP, we decided to present our provocative conclusions in this complex case. This case shows that, in patients taking drug combinations and having preexisting cardiovascular risks, physicians should be aware of possible unlikely adverse drug reactions. On our way from case reports to quality management of drug treatment, controversial discussions are important to classify severe adverse drug reactions. As well, further research is needed to elucidate the underlying physiological mechanisms. We definitely agree with Dr Crockford that clinicians should not change their practice with regard to lorazepam in general. Lorazepam is an important and useful drug in daily psychiatric clinical work. As with any drug, it can have side effects, some of which may be rare and peculiar.
Marc Ziegenbein, MD Stefan Kropp, MD Hanover, Germany

Lithium-Associated Anencephaly
Dear Editor: The most common congenital malformation (CMF) associated with lithium is Ebstein's anomaly. Other reported effects on the fetus are poor respiratory effort, cyanosis, rhythm disturbances, nephrogenic diabetes insipidus, thyroid dysfunction, hypoglycemia, hyperbilirubinemia, floppy baby syndrome, and large-for-gestational-age infants (1) . Neural tube defects have not been reported in humans.
Case Report
A woman, aged 21 years, with no medical or psychiatric history developed acute-onset manic illness that was initially treated with haloperidol (dosage unknown) and lasted for 3 weeks. She presented to our services with neuroleptic malignant syndrome and was treated with bromocriptine up to 15 mg daily, lorazepam up to 6 mg daily, and supportive management. She improved without any neurologic sequel and was started on lithium.
She remained euthymic on lithium 900 mg daily for 2 years (her serum levels were monitored regularly). She married during this period and had genetic counselling (wherein she was advised to practise contraception and to stop taking lithium if she planned a pregnancy). However, owing to contraceptive failure, she conceived. The patient and her husband decided to continue the pregnancy, despite repeat counselling. She stopped taking lithium before 8 completed weeks of pregnancy.
An investigation profile (specifically, HIV, Venereal Disease Research Laboratory slide test, TORCH Screen, hepatitis B antigen, hemogram, renal and liver function tests, and blood sugar level) was normal. She started taking folic acid, calcium, and iron supplements at approximately 8 weeks. Ultrasonography at 12 weeks showed a live fetus, aged 9 weeks. Ultrasonography at 20 weeks showed a live fetus, aged 16 weeks, with evidence of a supraorbital cranial bony defect (suggesting anencephaly) along with a retroplacental hypoechoic lesion, 4 cm × 3 cm in size (suggesting a retroplacental hematoma). Repeat ultrasonography at 23 weeks showed additional evidence of widening of the lower part of the spine. Because anencephaly was present in the fetus, the patient was advised to terminate the pregnancy medically. The patient refused and dropped out of treatment.
Discussion
Animal, but not human, studies have found lithium to be associated with increased neural tube defects manifesting as exencephaly (2) . Anencephaly has been seen in only one animal study (3), whereas evidence for association with exencephaly is more robust (2). However, sonographic and pathologic evidence points to a close link between exencephaly and anencephaly, with exencephaly being seen as a stage in the development of anencephaly (4).
Our patient became pregnant while taking lithium, and the fetus developed anencephaly. The possible association of anencephaly with lithium in this patient cannot be ruled out, owing to the temporal relation of lithium use in the first 6 to 8 weeks of pregnancy (the period of embryogenesis and most vulnerable period for developing CMF), the absence of a family history of CMF, and exencephaly-anencephaly being recognized as occuring in animal studies involving lithium.
Sandeep Grover, MD Chandigarh, India Nitin Gupta, MD, Burton upon Trent, UK
Aripiprazole-Induced Seizure
Dear Editor: Antipsychotics, both typical and atypical, have been known to lower seizure threshold. Aripiprazole is a novel atypical antipsychotic that is a partial agonist at dopamine D 2 and serotonin 1A (5-HT 1A ) receptors and has antagonist activity at the 5-HT 2 receptor. The risk of seizures with aripirazole is reported to be 0.1% (1), the lowest among atypical agents. Our literature search revealed no report of seizure induction with aripiprazole.
Case Report
Mr A, aged 31 years, was brought to the emergency department after a motor vehicle accident. He had lost control of his vehicle, which landed in a ditch. He carried a diagnosis of delusional disorder and major depression; aripiprazole 15 mg daily had recently been added to sertraline 150 mg daily that he had been taking for the past 2 years. Both the patient and his family suspected that a seizure had caused the accident, since they were perplexed by the circumstances of the crash. The patient denied that he had attempted suicide. Mr A was restarted on aripiprazole while he was in the intensive care unit. About 3 weeks later, he had a witnessed partial complex seizure on the ward. There was no evidence of any medical cause for the seizure. His laboratory tests were within normal limits, except for a serum magnesium level of 1.7 mg/dL (the lower normal being 1.8 mg/dL). He was started on levetiracetam, and his aripiprazole was later discontinued, because it was considered to be the offending agent. The patient was subsequently transferred to the rehabilitation unit, where he stayed seizure-free. He was discharged home after an adequate recovery.
Discussion
Seizure induction from antipsychotic drugs is not a new phenomenon. Several risk factors are known, including a personal or family history of epilepsy, head trauma, and concomitant use of another drug known to lower seizure threshold (2) . Since experience with aripiprazole is limited at this time, the risk of lowering of seizure threshold with this drug may actually be higher than reported in the premarketing studies. Our patient possibly had 2 separate seizures, one of which was the witnessed event that occured when the medication was reinitiated, making the likelihood high that aripiprazole was the offender.
Medical causes were ruled out, and there were no other implicated medications.
For optimum outcomes, high vigilence is needed to promptly identify the cause of seizures in patients taking psychotropic medications. The relevence of seizure secondary to aripiprazole needs further elucidation.
Prevalence of Bipolar Disorder and Major Depression Among Patients Seen in Primary and Secondary Care in Finland
Dear Editor: The underdiagnosis of bipolar disorder (BD) and its frequent misdiagnosis as major depressive disorder (MDD) appear to be major problems in patients with BD. Few studies focus on the prevalence of BD and MDD among primary care and psychiatric service patients. In Finland, more than 66% of the population visit a community health care centre during a year; 5% of the population are treated in primary care for a mental disorder, and 3% receive psychiatric treatment (1).
The Finnish Tampere Depression Project (TADEP) was a study that used the Present State Examination (9th version) to assess the prevalence of BD and MDD in primary and secondary care. The Index of Definition cutoff point of > 4 was used to identify cases of BD (ICD-8 diagnosis 296.1). A DSM-III-R assessment was also carried out. The study setting, patients, and data collection methods are reported in detail elsewhere (2, 3) .
Results
A total of 437 patients in primary care and 435 patients in secondary care were interviewed. In community health centres, the 1-month and 12-month prevalences of BD were 0.9% and 2.1%, respectively. In community mental health centres, the corresponding figures were 4.4% and 7.6%. In
